1. Introduction {#sec1-ijerph-17-03737}
===============

Irritable bowel syndrome (IBS), a functional disorder of the gastrointestinal tract, is formalized in the Rome criteria, which include chronic abdominal pain and altered bowel habits \[[@B1-ijerph-17-03737]\]. IBS is the most frequently diagnosed GI disorder \[[@B2-ijerph-17-03737]\] and the prevalence of IBS worldwide is 10% to 15% of the population \[[@B3-ijerph-17-03737]\]. In Taiwan, the prevalence of IBS (2003) was 22.1% according to the Rome II criteria, and no sex difference was found between subjects with and without IBS \[[@B4-ijerph-17-03737]\].

The pathophysiology of IBS is multifactorial and remains uncertain \[[@B5-ijerph-17-03737]\]. Recently, several studies have proposed new hypotheses of IBS pathophysiology, including genetics, psychosocial dysfunction (brain-gut axis dysfunction) and inflammation \[[@B6-ijerph-17-03737],[@B7-ijerph-17-03737],[@B8-ijerph-17-03737],[@B9-ijerph-17-03737]\]. Based on the inflammation hypothesis, epithelial cells of the inflamed intestinal mucosa are more permeable and lead to fluid leakage into the intestine. Compared with non-IBS subjects, IBS subjects have increased mast cells, lymphocytes, TNF alpha, IL-6, LIF, NGF, and IL-1 beta in the intestinal mucosa \[[@B9-ijerph-17-03737]\]. Therefore, *Helicobacter pylori* (*H. pylori*) infection has a potential pathogenic role in IBS given the significant overlaps between IBS and dyspepsia \[[@B10-ijerph-17-03737]\]. Approximately more than half of the world's population is estimated to be infected with *H. pylori,* which is a widespread gram-negative bacterium that colonizes the human gut \[[@B11-ijerph-17-03737]\]. *H. pylori* infection irritates immune neutrophils and lymphocytes in gut epithelial cells and liberates cytokines, including IL-1, IL-6, IL-8, IL-12, TNF-α and IFN-γ \[[@B12-ijerph-17-03737],[@B13-ijerph-17-03737]\]. Some studies have highlighted an increase in *H. pylori* infection rates in patients with IBS compared to healthy groups \[[@B14-ijerph-17-03737],[@B15-ijerph-17-03737]\]. However, other studies have disputed this finding and found no association between *H. pylori* infection and IBS \[[@B16-ijerph-17-03737],[@B17-ijerph-17-03737]\]. The inconsistent results were considered to be due to IBS caused by the interaction of multiple factors. Despite multiple investigations, data are conflicting, and no abnormality has been found to be specific for this disorder. Current evidence does not support an association between *H. pylori* infection and IBS \[[@B16-ijerph-17-03737]\]. Therefore, we used the randomized longitudinal health insurance dataset (LHID) selected from the National Health Insurance Research Database (NHIRD) to find IBS in the *H. pylori*-infected population in Taiwan.

2. Materials and Methods {#sec2-ijerph-17-03737}
========================

2.1. Data Source {#sec2dot1-ijerph-17-03737}
----------------

In 1995, the government of Taiwan implemented a single-payer universal health insurance system, the Taiwan National Health Insurance (NHI) program, which covers more than 99% of the 23 million residents in Taiwan and has been widely used in academic studies \[[@B18-ijerph-17-03737]\]. The NHIRD contains comprehensive, high-quality information, including epidemiological research, and information on diagnoses, prescription use, and health-care information, including inpatient/ambulatory claims, prescription claims, demographic data and hospitalization \[[@B19-ijerph-17-03737],[@B20-ijerph-17-03737],[@B21-ijerph-17-03737]\]. Data for our cohort study were obtained from the NHIRD, which has multiple data sources, is a powerful research engine with enriched dimensions and serves as a guiding light for real-world evidence-based medicine in Taiwan \[[@B22-ijerph-17-03737]\]. The International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) was used to define the diagnostic codes.

2.2. Sample Participants {#sec2dot2-ijerph-17-03737}
------------------------

As shown in [Figure 1](#ijerph-17-03737-f001){ref-type="fig"}, we identified patients aged 14 years or older with a newly diagnosed *H. pylori* infection (ICD-9-CM codes 041.86) in the period from 2000 to 2013. The ICD-9-CM diagnosis of *H. pylori* infection was based on endoscopic biopsy urease testing or non-invasive tests, such as urea breath testing. The diagnosis of *H. pylori* infection was confirmed at least twice. *H. pylori* infection is usually treated with triple eradication therapy (amoxicillin/metronidazole, levofloxacin/clarithromycin and a proton pump inhibitor) for at least two weeks to help prevent the bacteria from developing resistance to one particular antibiotic. Those with a documented *H. pylori* infection before 1 January 2000 or with incomplete medical information were excluded to ensure the data were from individuals with a first diagnosis of *H. pylori* infection. In Taiwan, the diagnoses of IBS (ICD-9-CM code: 564. 1) were made by board-certified gastroenterologists, and were diagnosed according to the serial versions of the Rome criteria \[[@B23-ijerph-17-03737]\]. The NHI administration randomly reviews the records of 1 in 100 ambulatory care visits and 1 in 15 inpatient claims to verify the accuracy of the diagnosis \[[@B24-ijerph-17-03737]\]. We also excluded people with a history of IBS. The comparison cohort consisted of patients randomly selected from the patient database without a history of *H. pylori* infection. For each identified patient with *H. pylori* infection, four comparison patients were randomly identified and frequency-matched according to the age, sex, and year of index date for the non-*H. pylori*-infected cohort.

2.3. Variables of Interest {#sec2dot3-ijerph-17-03737}
--------------------------

The sociodemographic variables used in this study comprised age, sex and urbanization level. The level of urbanization was divided into four levels (Level 1 is the most urbanized and level 4 is the least urbanized) based on the NHRID report. We defined baseline comorbidities, coronary artery disease (ICD-9-CM codes 410-414), cerebrovascular accident (ICD-9-CM codes 430-438), hypertension (ICD-9-CM codes 401-405), hyperlipidemia (ICD-9-CM codes 272), diabetes (ICD-9-CM codes 250), end-stage renal disease (ICD-9-CM codes 585.6), asthma (ICD-9-CM codes 493) and medication use of tetracycline (drug codes: AC04963100, AC049631G0, AC12059100, AC12639100, AC15791100, AC157911G0, AC22572100, AC225721G0), minocycline (drug codes: A032761100, A033214100, A035969100, A036813100, A043111100, AB40644100, AC33471100, AC35868100, AC36266100, AC36281100, AC36667100, AC36815100, AC36940100, AC38761100, AC39074100, AC39600100) and doxycycline (drug codes: A009397100, AC07233100, AC12782100, AC16227100, AC19254100, AC192541G0, AC23648100, AC236481G0, AC24085100, AC31219100, AC34900100, AC35692100, AC356921G0).

2.4. Statistical Analysis {#sec2dot4-ijerph-17-03737}
-------------------------

The distribution of sociodemographic data and comorbidities were compared between the *Helicobacter pylori* infection (HPI) cohort and the comparison cohort using the chi-squared test to examine categorical variables and the t-test to examine continuous variables. Kaplan--Meier analysis was performed to estimate IBS in these two cohorts, and the log-rank test examined the difference between the curves. We computed the incidence density rate of IBS (per 100,000 person-years) at follow-up for each cohort. Univariable and multivariable Cox proportion hazard regression models were used to examine the effect of HPI on the risk of IBS, shown as a hazard ratio (HR) with a 95% confidence interval (CI). The multivariable models were adjusted for age, sex, urbanization level and all comorbidities. Further analysis was performed to assess the effect of the dose response of *H. pylori* infection to the antibiotic medicine that was prescribed on the risk of IBS. All statistical analyses were performed using SPSS software (Version 22.0; SPSS Inc., Chicago, IL, USA). The comparisons used the significance level of 0.05 for two-sided testing.

2.5. Data Availability {#sec2dot5-ijerph-17-03737}
----------------------

Data are available from the National Health Insurance Research Database (NHIRD) published by the Taiwan National Health Insurance (NHI) Administration. Due to legal restrictions imposed by the government of Taiwan in relation to the "Personal Information Protection Act", data cannot be made publicly available. Requests for data can be sent as a formal proposal to the NHIRD (<http://www.mohw.gov.tw/cht/DOS/DM1.aspx?f_list_no=812>).

2.6. Ethics Statement {#sec2dot6-ijerph-17-03737}
---------------------

This study was approved by the Institutional Review Board of the Tri-Service General Hospital (TSGH IRB No. 2-105-05-082; Taipei, Taiwan).

3. Results {#sec3-ijerph-17-03737}
==========

[Table 1](#ijerph-17-03737-t001){ref-type="table"} shows the demographic characteristics of both cohorts. The mean age was 57.71 ± 17.01 years in the study cohort and 57.70 ± 18.40 years in the control cohort. The difference was not significant (*p* = 0.593). In addition, there was no significant difference in sex or age for both groups. Regarding insurance premiums (in New Taiwan dollars (NT\$)) in both cohorts, almost all of the enrolled patients were in the \<18,000 group (98.25%), followed by the 18,000 to 34,999 group (1.44%) and the \>35,000 group (0.31%). There was no significant difference in the insurance premiums (NT\$) in either group (*p* = 0.136). In terms of the comorbidity, patients with *H. pylori* infection had lower rates of coronary artery disease (CAD), cerebrovascular accident (CVA), hypertension (HTN), hyperlipidemia, diabetes mellitus (DM) and asthma than the control patients. The CCI_R value was 1.27 ± 0.77 in the study cohort and 0.27 ± 0.69 in the control cohort (*p* \< 0.001). In addition, more individuals in the study cohort than in the control cohort lived in southern and eastern Taiwan and lower urbanized areas, and received therapy in local hospitals (*p* \< 0.001).

The IBS rate was calculated by the Kaplan--Meier method ([Figure 2](#ijerph-17-03737-f002){ref-type="fig"}). The results showed that the study cohort had a significantly higher IBS rate than the control cohort (log-rank test (p \< 0.001)). [Table 2](#ijerph-17-03737-t002){ref-type="table"} shows the Cox regression analysis of the risk factors for IBS. After adjusting for *H. pylori* infection, sex, age group, insurance premium and pre-existing comorbidities, including sleep apnea, HTN, and only *H. pylori* infection (aHR = 3.108, 95% confidence interval (CI) = 1.934--4.995, *p* \< 0.001), patients in the study cohort showed an increased risk of IBS diagnosis compared with the control cohort. In addition, patients with CVA had a decreased risk of developing IBS than those without CVA (aHR = 3.121, *p* \< 0.001). Patients with other comorbidities, age groups and insurance premiums, as well as other chronic diseases, were not significantly associated with IBS diagnosis according to the hazard ratios (all *p* \> 0.05).

In the subgroup analysis comparing patients with and without *H. pylori* infection ([Table 3](#ijerph-17-03737-t003){ref-type="table"}), the overall incidence of IBS was 109.5 per 100,000 person-years in the study cohort and 33.83 per 100,000 person-years in the control cohort. Female and male *H. pylori*-infected patients showed an increased risk of developing IBS (total aHR = 3.108, *p* \< 0.001; 3.074 in the corresponding age group of females, *p* \< 0.001; 3.228 in the corresponding age group of males, *p* = 0.003). In the age group analysis, patients with *H. pylori* infection in the 44 to 64-year age group were independently associated with an increased risk following IBS diagnosis compared with patients without *H. pylori* infection (aHR= 4.971, *p* \< 0.001). In the insured premium group analysis, *H. pylori*-infected patients in the \<18,000 group showed an increased risk of developing IBS (aHR = 3.108, *p* \< 0.001). In the pre-existing condition group analysis, *H. pylori*-infected patients with CAD, CVA, HTN or DM displayed an increased risk of developing IBS (aHR = 3.268, *p* \< 0.001 in CAD; aHR = 3.605, *p* \< 0.001 in CVA; aHR= 4.702, *p* \< 0.001 in HTN; aHR = 15.952, *p* \< 0.001 in DM). In the season group analysis, patients infected with *H. pylori* in the summer and autumn groups showed an increased risk of developing IBS (aHR = 4.035, *p* = 0.001 in summer; aHR = 3.594, *p* = 0.009 in autumn). In the level of care group analysis, *H. pylori*-infected patients in the hospital center and regional hospital groups displayed an increased risk of developing IBS compared with those in clinics (aHR = 5.402, *p* = 0.003 in hospital center; aHR = 3.462, *p* \< 0.001 in regional hospital). Patients with *H. pylori* infection were associated with a higher risk of IBS than patients without *H. pylori* infection, and patients with *H. pylori* infection who received aggressive eradication therapy had a decreased risk of IBS compared with patients with *H. pylori* infection who did not receive eradication therapy (adjusted HR 0.464; 95% CI 0.148--0.963, *p* = 0.037) ([Table 4](#ijerph-17-03737-t004){ref-type="table"}).

4. Discussion {#sec4-ijerph-17-03737}
=============

This is the first large-scale, population-based study with long-term follow-up on the association between *H. pylori* infection and the risk of IBS. After adjusting for covariates, the overall adjusted HR was 3.108 (95% CI: 1.934--4.995, P \< 0.001). In other words, adult patients with *H. pylori* infection had a nearly 3.1-fold increased risk of developing IBS than those without *H. pylori* infection. The Kaplan--Meier analysis revealed that the study subjects had a significantly higher 14-year IBS rate than the controls after adjusting for potential confounders; this is further strong evidence for a potential association between IBS and *H. pylori* infection.

*H. pylori* can produce bacterial urease, which hydrolyses in gastric luminal urea to form ammonia, which helps neutralize gastric acid and form a protective cloud around the organism, enabling it to penetrate the gastric mucus layer \[[@B25-ijerph-17-03737]\]. Several studies have reported an association between *H. pylori* infection and the incidence of gastric cancer and colorectal cancer \[[@B26-ijerph-17-03737],[@B27-ijerph-17-03737]\]. Diagnostic testing for *H. pylori* includes endoscopic biopsy urease testing, urea breath testing, stool antigen assay, and serological ELISA testing \[[@B28-ijerph-17-03737]\]. *H. pylori* infection is usually treated with at least two different antibiotics at once to help prevent the bacteria from developing resistance to one particular antibiotic \[[@B29-ijerph-17-03737]\]. Triple eradication therapy and bismuth quadruple treatment regimens are popular in Taiwan.

The pathogenesis of IBS is still uncertain. In our study, we tried to find a relationship between IBS and *H. pylori* infection. It seems that chronic inflammation caused by *H. pylori* infection is related to the pathogenesis of atrophic gastritis, intestinal metaplasia and peptic ulcers \[[@B30-ijerph-17-03737]\]. *H. pylori* infection may increase inflammatory marker levels \[[@B31-ijerph-17-03737]\], increase mast cell activation, and then affect the gastric mucosa and nerve remodeling \[[@B32-ijerph-17-03737],[@B33-ijerph-17-03737],[@B34-ijerph-17-03737]\], causing visceral hypersensitivity symptoms such as those of IBS \[[@B35-ijerph-17-03737],[@B36-ijerph-17-03737],[@B37-ijerph-17-03737],[@B38-ijerph-17-03737]\].

According to our study, patients with *H. pylori* infection who did not receive eradication therapy had a higher risk of IBS than the non-*H. pylori*-infected cohort. (adjusted HR 4.16; 95% CI 2.508--6.900). Patients with *H. pylori* infection who received eradication therapy had a lower risk of IBS than the untreated group (adjusted HR 0.464; 95% CI 0.148--0.963). In the long term observation, the risk of IBS is reduced in the H. pylori infection-treated population. There seems to be some connections between *H. pylori* infection and IBS. Clinically, it is also possible to add a supplemental *H. pylori* test for drug treatment to reduce the symptoms of IBS.

The association between IBS and *H. pylori* has been challenged. For example, *H. pylori* is thought to commonly influence the upper GI tract rather than the lower GI tract. Additionally, findings by Xiong indicate that there is no relationship between *H. pylori* infection and IBS \[[@B39-ijerph-17-03737]\]. However, although this multi-center retrospective study considered eradication medicine resistance, the cohort was only followed up for one year, and there was no follow-up after second-line drugs were administered. Other data have shown that the association could be fortuitous given the widespread prevalence of *H. pylori* infection globally \[[@B40-ijerph-17-03737]\]. Clinically, *H. pylori* infection drugs fail or resistance develops in approximately 10% of patients \[[@B41-ijerph-17-03737]\], and there are other many reasons for failure. Perhaps our big data research can reduce these factors.

This study has a number of strengths. First, the sample size was very large, which enhanced the statistical power of the data. We used stratified analyses based on the confounding factors of age, comorbidities, and a wide range of demographic characteristics. Second, because we used a nationwide database with a very high coverage rate, almost all patients' follow-up data were available. Third, the population-based data were considered representative of the general population in Taiwan.

Our study also had some limitations. First, this was a retrospective cohort study; therefore, it has lower statistical quality. Bias from unknown confounders and errors of primary records may have affected our results, and a well-designed prospective, randomized, controlled study is needed to help establish causal relationships. Second, the NHIRD does not report information such as clinical symptoms, signs, or laboratory data, which may help distinguish different types of IBS for further analysis.

5. Conclusions {#sec5-ijerph-17-03737}
==============

Patients with *H. pylori* infection have a higher proportion of IBS, and aggressive *H. pylori* infection eradication therapy can reduce the risk of IBS. Further underlying biological mechanistic research is needed. Clinically, IBS patients seem to be able to undergo routine *H. pylori* diagnostic tests to determine the direction of treatment.
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ijerph-17-03737-t001_Table 1

###### 

Characteristics of the study population at the baseline.

  HPI                          Total           With            Without         *P*                         
  ---------------------------- --------------- --------------- --------------- --------- -------- -------- ---------
  **Total**                    13,345                          2669            20.00     10,676   80.00    
  **Gender**                                                                                               0.999
  Male                         8790            65.87           1758            65.87     7032     65.87    
  Female                       4555            34.13           911             34.13     3644     34.13    
  **Age (years)**              57.54 ± 18.13   57.71 ± 17.01   57.70 ± 18.40   0.593                       
  **Age group (years)**                                                                                    0.999
  \<44                         3350            25.10           670             25.10     2680     25.10    
  44--64                       4715            35.33           943             35.33     3772     35.33    
  ≧65                          5280            39.57           1056            39.57     4224     39.57    
  **Insured premium (NT\$**)                                                                               0.136
  \<18,000                     13,111          98.25           2613            97.90     10,498   98.33    
  18,000--34,999               192             1.44            49              1.84      143      1.34     
  ≧35,000                      42              0.31            7               0.26      35       0.33     
  **CAD**                                                                                                  \<0.001
  Without                      12,087          90.57           2508            93.97     9579     89.72    
  With                         1258            9.43            161             6.03      1097     10.28    
  **CVA**                                                                                                  \<0.001
  Without                      12,312          92.26           2583            96.78     9729     91.13    
  With                         1033            7.74            86              3.22      947      8.87     
  **HTN**                                                                                                  \<0.001
  Without                      10,738          80.46           2247            84.19     8491     79.53    
  With                         2607            19.54           422             15.81     2185     20.47    
  **Hyperlipidemia**                                                                                       0.001
  Without                      12,904          96.70           2609            97.75     10,295   96.43    
  With                         441             3.30            60              2.25      381      3.57     
  **DM**                                                                                                   0.031
  Without                      11,238          84.21           2284            85.58     8954     83.87    
  With                         2107            15.79           385             14.42     1722     16.13    
  **ESRD**                                                                                                 \-
  Without                      13,345          100.00          2669            100.00    10,676   100.00   
  With                         0               0.00            0               0.00      0        0.00     
  **Asthma**                                                                                               0.001
  Without                      13,098          98.15           2640            98.91     10,458   97.96    
  With                         247             1.85            29              1.09      218      2.04     
  **CCI_R**                    0.47 ± 0.81     1.27 ± 0.77     0.27 ± 0.69     \<0.001                     
  **Season**                                                                                               \<0.001
  Spring (Mar--May)            3466            25.97           628             23.53     2838     26.58    
  Summer (Jun--Aug)            3264            24.46           674             25.25     2590     24.26    
  Autumn (Sep--Nov)            3019            22.62           696             26.08     2323     21.76    
  Winter (Dec--Feb)            3596            26.95           671             25.14     2925     27.40    
  **Location**                                                                                             \<0.001
  Northern Taiwan              4850            36.34           835             31.29     4015     37.61    
  Middle Taiwan                3674            27.53           462             17.31     3212     30.09    
  Southern Taiwan              3744            28.06           1,005           37.65     2739     25.66    
  Eastern Taiwan               1014            7.60            366             13.71     648      6.07     
  Outlets islands              63              0.47            1               0.04      62       0.58     
  **Urbanization level**                                                                                   \<0.001
  1 (The highest)              4030            30.20           762             28.55     3268     30.61    
  2                            5998            44.95           1328            49.76     4670     43.74    
  3                            1202            9.01            360             13.49     842      7.89     
  4 (The lowest)               2115            15.85           219             8.21      1896     17.76    
  **Level of care**                                                                                        \<0.001
  Hospital center              4019            30.12           685             25.67     3334     31.23    
  Regional hospital            5786            43.36           1374            51.48     4412     41.33    
  Local hospital               3540            26.53           610             22.86     2930     27.44    

*P*: Chi-square/Fisher exact test on category variables and t-test on continue variables. HPI: *Helicobacter pylori* infection; NT\$: New Taiwan dollar; CAD: coronary artery disease; CVA: cerebrovascular accident; HTN: hypertension; DM: diabetes mellitus; ESRD: end-stage renal disease; CCI_R: Charlson comorbidity index removed coronary artery disease, cerebrovascular accident, hypertension, hyperlipidemia, diabetes mellitus, end-stage renal disease, and asthma.

ijerph-17-03737-t002_Table 2

###### 

Factors of irritable bowel syndrome (IBS) by using Cox regression.

  Variables                    Crude HR    95% CI   95% CI   *P*       Adjusted HR   95% CI   95% CI   *P*
  ---------------------------- ----------- -------- -------- --------- ------------- -------- -------- ---------
  **HPI**                                                                                              
  Without                      Reference                               Reference                       
  With                         2.887       1.801    4.626    \<0.001   3.108         1.934    4.995    \<0.001
  **Gender**                                                                                           
  Male                         0.873       0.539    1.412    0.579     1.075         0.474    1.268    0.310
  Female                       Reference                               Reference                       
  **Age group (years)**                                                                                
  \<44                         Reference                               Reference                       
  44--64                       0.877       0.457    1.683    0.693     1.112         0.566    2.187    0.757
  ≧65                          0.700       0.378    1.295    0.256     0.817         0.416    1.605    0.557
  **Insured premium (NT\$**)                                                                           
  \<18,000                     Reference                               Reference                       
  18,000--34,999               0.000       \-       \-       0.507     0.000         \-       \-       0.966
  ≧35,000                      0.000       \-       \-       0.777     0.000         \-       \-       0.987
  **CAD**                                                                                              
  Without                      Reference                               Reference                       
  With                         0.994       0.409    1.952    0.778     1.194         0.535    2.663    0.665
  **CVA**                                                                                              
  Without                      Reference                               Reference                       
  With                         2.279       1.268    4.094    0.006     3.121         1.670    5.834    \<0.001
  **HTN**                                                                                              
  Without                      Reference                               Reference                       
  With                         1.537       0.298    2.094    0.285     1.552         0.286    2.065    0.077
  **Hyperlipidemia**                                                                                   
  Without                      Reference                               Reference                       
  With                         1.042       0.506    2.894    0.366     1.048         0.561    3.317    0.432
  **DM**                                                                                               
  Without                      Reference                               Reference                       
  With                         1.462       0.921    2.965    0.054     1.488         0.729    2.042    0.064
  **ESRD**                                                                                             
  Without                      Reference                               Reference                       
  With                         \-          \-       \-       \-        \-            \-       \-       \-
  **Asthma**                                                                                           
  Without                      Reference                               Reference                       
  With                         1.475       0.361    6.018    0.588     1.809         0.433    7.550    0.416
  **CCI_R**                    0.905       0.775    1.058    0.209     1.017         0.875    1.184    0.309
  **Season**                                                                                           
  Spring                       Reference                               Reference                       
  Summer                       2.068       0.668    2.942    0.829     2.142         0.626    2.886    0.665
  Autumn                       1.532       0.573    2.037    0.064     1.543         0.578    2.147    0.074
  Winter                       1.389       1.175    1.864    0.020     1.413         1.186    1.919    0.030
  **Location**                                                                                         
  Northern Taiwan              Reference                                                               
  Middle Taiwan                2.289       1.238    4.231    0.008                                     
  Southern Taiwan              1.532       0.788    2.980    0.209                                     
  Eastern Taiwan               1.893       0.779    4.605    0.159                                     
  Outlets islands              0.000       \-       \-       0.968                                     
  **Urbanization level**                                                                               
  1 (The highest)              2.294       1.190    4.423    0.013     1.536         0.259    1.701    0.092
  2                            1.378       0.535    3.551    0.507     1.331         0.291    1.696    0.084
  3                            1.092       0.581    2.052    0.785     0.581         0.235    1.438    0.240
  4 (The lowest)               Reference                               Reference                       
  **Level of care**                                                                                    
  Hospital center              2.514       1.280    4.937    0.007     1.790         0.498    2.698    0.396
  Regional hospital            1.690       0.890    3.212    0.109     1.590         0.275    2.224    0.177
  Local hospital               Reference                               Reference                       

HR: hazard ratio; CI: confidence interval; HPI: *Helicobacter pylori* infection; NT\$: New Taiwan dollar; CAD: coronary artery disease; CVA: cerebrovascular accident; HTN: hypertension; DM: diabetes mellitus; ESRD: end-stage renal disease; CCI_R: Charlson comorbidity index removed coronary artery disease, cerebrovascular accident, hypertension, hyperlipidemia, diabetes mellitus, end-stage renal disease, and asthma. Adjusted HR: Adjusted variables are listed. *P*: Chi-square/Fisher exact test on category variables and t-test on continue variables.
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###### 

Factors of irritable bowel syndrome (IBS) stratified by variables listed in the table by using Cox regression.

                               With HPI   Without HPI   With vs. Without                                                                
  ---------------------------- ---------- ------------- ------------------ ---- ------------ ------- -------- -------- ------- -------- ---------
  **Total**                    31         28,376.11     109.25             39   115,278.73   33.83   3.229    3.108    1.934   4.995    \<0.001
  **Gender**                                                                                                                            
  Male                         19         18,081.31     105.08             24   74,553.61    32.19   3.264    3.228    1.487   7.010    0.003
  Female                       12         10,294.81     116.56             15   40,725.13    36.83   3.165    3.074    1.678   5.629    \<0.001
  **Age group (years)**                                                                                                                 
  \<44                         7          5265.65       132.94             8    20,134.93    39.73   3.346    3.269    1.130   9.458    0.029
  44--64                       13         8407.04       154.63             10   34,593.43    28.91   5.349    4.971    2.148   11.503   \<0.001
  ≧65                          11         14,703.42     74.81              21   60,550.38    34.68   2.157    2.201    1.506   4.589    0.035
  **Insured premium (NT\$**)                                                                                                            
  \<18,000                     31         27,747.83     111.72             39   113,542.93   34.35   3.253    3.108    1.934   4.995    \<0.001
  18,000--34,999               0          624.29        0.00               0    1380.70      0.00    \-       \-       \-      \-       \-
  ≧35,000                      0          4.00          0.00               0    355.11       0.00    \-       \-       \-      \-       \-
  **CAD**                                                                                                                               
  Without                      26         25,383.09     102.43             34   102,503.61   33.17   3.088    1.654    0.246   11.141   0.605
  With                         5          2993.02       167.06             5    12,775.13    39.14   4.268    3.268    1.986   5.378    \<0.001
  **CVA**                                                                                                                               
  Without                      22         25,674.01     85.69              29   103,869.28   27.92   3.069    2.475    1.427   5.098    0.039
  With                         9          2702.10       333.07             10   11,409.45    87.65   3.800    3.605    2.127   6.110    \<0.001
  **HTN**                                                                                                                               
  Without                      24         20,486.19     117.15             34   83,677.62    40.63   2.883    2.775    1.639   4.697    \<0.001
  With                         7          7889.93       88.72              5    31,601.12    15.82   5.607    4.702    1.463   15.116   \<0.001
  **Hyperlipidemia**                                                                                                                    
  Without                      31         27,470.42     112.85             38   111,100.13   34.20   3.299    3.186    1.977   5.133    \<0.001
  With                         0          905.70        0.00               1    4178.61      23.93   0.000    0.000    \-      \-       0.752
  **DM**                                                                                                                                
  Without                      25         22,236.72     112.43             37   90,656.96    40.81   2.755    2.655    1.592   4.427    \<0.001
  With                         6          6139.39       97.73              2    24,621.78    8.12    12.031   15.952   2.797   90.961   \<0.001
  **ESRD**                                                                                                                              
  Without                      31         28,376.11     109.25             39   115,278.73   33.83   3.229    3.108    1.934   4.995    \<0.001
  With                         0          0.00          \-                 0    0.00         \-      \-       \-       \-      \-       \-
  **Asthma**                                                                                                                            
  Without                      30         27,885.94     107.58             38   113,027.76   33.62   3.200    3.050    1.884   4.937    \<0.001
  With                         1          490.17        204.01             1    2250.98      44.43   4.592    4.497    0.009   12.589   0.747
  **Season**                                                                                                                            
  Spring                       7          5786.86       120.96             12   24,237.41    49.51   2.443    2.197    0.847   5.700    0.105
  Summer                       12         6943.36       172.83             13   28,874.00    45.02   3.839    4.035    1.809   8.999    0.001
  Autumn                       8          9022.10       88.67              9    34,938.86    25.76   3.442    3.594    1.367   9.447    0.009
  Winter                       4          6623.80       60.39              5    27,228.47    18.36   3.289    2.658    0.685   10.312   0.158
  **Urbanization level**                                                                                                                
  1 (The highest)              9          7304.40       123.21             6    32,885.51    18.25   6.753    6.726    2.272   19.907   0.001
  2                            13         14,376.62     90.42              14   51,741.11    27.06   3.342    3.069    1.434   6.568    0.004
  3                            2          2293.89       87.19              4    9283.94      43.09   2.024    1.936    0.336   11.480   0.453
  4 (The lowest)               7          4401.19       159.05             15   21,368.18    70.20   2.266    1.947    0.779   4.865    0.154
  **Level of care**                                                                                                                     
  Hospital center              7          8402.69       83.31              6    36,328.46    16.52   5.044    5.402    1.774   16.446   0.003
  Regional hospital            17         13,757.36     123.57             16   52,465.12    30.50   4.052    3..462   1.735   6.909    \<0.001
  Local hospital               7          6216.06       112.61             17   26,485.15    64.19   1.754    1.590    0.645   3.917    0.313

PYs: Person-years; Adjusted HR: Adjusted Hazard ratio; CI: confidence interval; HPI: *Helicobacter pylori* infection; CAD: coronary artery disease; CVA: cerebrovascular accident; HTN: hypertension; DM: diabetes mellitus; ESRD: end-stage renal disease. Adjusted for the variables listed in [Table 2](#ijerph-17-03737-t002){ref-type="table"}.
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###### 

Factors of irritable bowel syndrome (IBS) among study population and PHI cohort by using Cox regression.

                            HPI Cohort and Comparison Cohort   HPI Cohort                                                                     
  -------------------- ---- ---------------------------------- ------------ ----------- ------- ------- --------- ----------- ------- ------- -------
  Without HPI          39   28,376.11                          137.44       Reference                                                         
  With HPI             31   28,376.11                          109.25                                                                         
  without medication   25   16,605.68                          150.55       4.160       2.508   6.900   \<0.001   Reference                   
  with medication      6    11,770.44                          50.98        0.916       0.241   2.590   0.344     0.464       0.148   0.963   0.037

PYs: Person-years; Adjusted HR: Adjusted Hazard ratio; HPI: *Helicobacter pylori* infection. Adjusted for the variables listed in [Table 2](#ijerph-17-03737-t002){ref-type="table"}; CI: confidence interval.
